HNWAG
RCUS icon

High Net Worth Advisory Group’s Arcus Biosciences RCUS Stock Holding History

High Net Worth Advisory Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$10.3K – 485
2022
Q4 		$10.3K Buy
+500
New +$13.8K ﹤0.01% 496

Other funds holding RCUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

High Net Worth Advisory Group's RCUS Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 500 shares — an estimated $10.3K sold.

High Net Worth Advisory Group first reported a position in RCUS in Q4 2022 and held it in 1 quarter. The position peaked at $10.3K in Q4 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Arcus Biosciences shares in Q1 2023, an estimated $10.3K.
  • High Net Worth Advisory Group first reported a position in Arcus Biosciences in Q4 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's Arcus Biosciences position peaked at $10.3K in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.